Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878896 | 1.00 | ALDH1A1 (0.44) | ALDH1A1KDM4ETDP1LMNAL3MBTL1 | |
| SCHEMBL27031407 | 0.88 | CA1 (0.40) | ALDH1A1KDM4ETDP1LMNAL3MBTL1 | |
| SCHEMBL17318151 | 0.82 | TSHR (0.45) | ALDH1A1KDM4ETDP1LMNAL3MBTL1 | |
| SCHEMBL6942043 | 0.80 | CA1 (0.44) | ALDH1A1KDM4ETDP1LMNAL3MBTL1 | |
| SCHEMBL31364096 | 0.80 | CA1 (0.49) | ALDH1A1KDM4ETDP1LMNAL3MBTL1 | |
| SCHEMBL235717 | 0.79 | LMNA (0.47) | ALDH1A1KDM4ETDP1LMNAL3MBTL1 | |
| SCHEMBL4225144 | 0.79 | HSD11B1 (0.41) | L3MBTL1CA1CA2 | |
| SCHEMBL31204254 | 0.78 | CA1 (0.46) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2MAPK1 | |
| SCHEMBL1411728 | 0.78 | CA1 (0.46) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2MAPK1 | |
| SCHEMBL4581096 | 0.78 | ACHE (0.55) | ALDH1A1LMNAL3MBTL1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289781-A1 | TRIFLUOROMETHANESULFONYLATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANESULFONYL COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2025-09-18 | — | — | US | disclosed |
| CN-119137096-A | Trifluoromethanesulfonyl a composition of the agent trifluoromethanesulfonyl oxy compounds or Process for producing trifluoromethanesulfonyl compound | 中央硝子株式会社 | 2024-12-13 | — | — | CN | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023214552-A1 | TRIFLUOROMETHANE SULFONYLATION AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANE SULFONYL COMPOUND | セントラル硝子株式会社 | 2023-11-09 | — | — | WO | disclosed |
| WO-2023214552-A1 | TRIFLUOROMETHANE SULFONYLATION AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANE SULFONYL COMPOUND | セントラル硝子株式会社 | 2023-11-09 | — | — | WO | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2022197892-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | TANGO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| EP-2190826-A2 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009032668-A2 | 2 -BIPHENYLAMINO-4 -AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | ALDH1A1 520/4885KDM4E 3775/4885TDP1 82/4885 |
| US-20250289781-A1 | TRIFLUOROMETHANESULFONYLATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANESULFONYL COMPOUND | AFF1, BRAF, AFF2 | ALDH1A1 2621/4885KDM4E 2920/4885TDP1 1156/4885 |
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2943/4885KDM4E 3425/4885TDP1 3039/4885 |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, IGFBP1, IRS1 | ALDH1A1 329/4885KDM4E 904/4885TDP1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.